New Painkiller That Combines Oxycodone and Naloxone Approved by FDA


A new painkiller that combines oxycodone and naloxone was approved by the U.S. Food and Drug Administration (FDA) on Wednesday. Naloxone was included in the drug to block the euphoric effects of oxycodone, making it less appealing to abuse.

The drug, Targiniq ER, is made by Purdue Pharma, which also makes OxyContin, the Los Angeles Times reports. Targiniq ER can be crushed and then snorted or injected. If the pills are crushed, the naloxone becomes active.

“Targiniq ER can still be abused, including when taken orally (by mouth), which is currently the most common way oxycodone is abused,” according to a statement by the FDA. Targiniq is expected to “deter, but not totally prevent” abuse, the FDA said.

“The FDA is committed to combating the misuse and abuse of all opioids,” Sharon Hertz, Deputy Director of the FDA’s Division of Anesthesia, Analgesia and Addiction Products, said in the statement. “The development of opioids that are harder to abuse is needed in order to help address the public health crisis of prescription drug abuse in the U.S.”

Dr. Andrew Kolodny, President of Physicians for Responsible Opioid Prescribing, told the newspaper he is concerned that doctors who believe Targiniq is safe may be more likely to prescribe it than to look for alternatives. “If we really want to turn this epidemic around, the most important thing is to stop creating new cases of addiction,” he said. “Coming up with new gimmicks isn’t going to help.”

Lynn Webster, a pain and addiction specialist and former president of the American Academy of Pain Medicine, said that while abuse-deterrent drugs such as Targiniq are not a good substitute for judicious prescribing, “the obvious alternative is not to have abuse-deterrent formulations, and I don’t know anyone who would find that preferable.”

    User Picture

    Maureen Chrzanowski

    November 24, 2017 at 7:40 PM

    Andrew Kolodny needs to take his personal agenda whether fame or
    Whatever sinister action he is planning it needs careful reconsideration
    1. Dependence
    Is normal reaction to discontinuing
    Opiods. It is not addiction. Chronic pain patients are currently being neglected or receiving poor inadequate adressment of their pain need. They are and continue to be the victims of this mass hysteria in an atmosphere of misunderstandings by patients and practitioner alike.
    2.the definition of addiction needs to be made clear. Addiction is not dependence.
    Strategies aimed
    To improve the situation should be carefully thought out. This a come complicated than most people realized. I cannot be accomplished quickly. Rush to legislation which had the Potential of harming millions just trying to have some type of life quality is wrong. Let’s back up and have open hearings where cpp tell their stories and illustrate how this has affected them expert testimony (from those active pain management practitioners not
    Md who are administrators only) and well designed s repaoducible research. If far more valuable
    Then rushing and reinforcing the current hysterical fear based climate. Stop the madness!

    User Picture

    allen border

    July 12, 2017 at 8:20 AM

    I was on oxycontin, oxycodone for quite a long time because of the serious agony I’m in always. Not used to be I dependent on it. Truth be told, I quit taking it without any weaning period on the grounds that another agony facility doc asked me to. All that did was cause so much agony I needed to bite the dust. I needed to change to morphine, and it doesn’t give about the alleviation I had with the oxy. I have stopped going anyplace and don’t go out from that point forward, because of the agony. It’s been no less than 2 years now. Walmart won’t acknowledge oxy as a component of their arrangement, accordingly I endure more. Reveal to me that is reasonable.

Leave a Comment

Please leave a comment below to contribute to the discussion. If you have a specific question, please contact a Parent Specialist, who will provide you with one-on-one help.

Your email address will not be published. Required fields are marked *